ASCENTAGE PHARMA GROUP(AAPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AAPG ASCENTAGE PHARMA GROUP

Market Closed 01-16 16:00:00 EST

27.05

-0.25

-0.92%

盘后27.05

+0.000.00%

17:16 EST

High27.05	Low26.80	Vol4.59K
Open27.04	D1 Closing27.30	Amplitude0.92%
Mkt Cap2.52B	Tradable Cap1.94B	Total Shares93.33M
T/O123.88K	T/O Rate0.01%	Tradable Shares71.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"ASCENTAGE PHARMA GROUP","latestPrice":27.05,"timestamp":1768597200000,"preClose":27.3,"halted":0,"volume":4594,"hourTrading":{"tag":"盘后","latestPrice":27.05,"preClose":27.05,"latestTime":"17:16 EST","volume":23,"amount":621.69,"timestamp":1768601764093,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.009157509157509158,"floatShares":71582800,"shares":93330405,"eps":-1.979486,"marketStatus":"Market Closed","change":-0.25,"latestTime":"01-16 16:00:00 EST","open":27.04,"high":27.05,"low":26.8,"amount":123875.94665,"amplitude":0.009158,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.979486,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":27.3,"postHourTrading":{"tag":"盘后","latestPrice":27.05,"preClose":27.05,"latestTime":"17:16 EST","volume":23,"amount":621.69,"timestamp":1768601764093,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.3864937172487957},"requestUrl":"/m/hq/s/AAPG/wiki","defaultTab":"wiki","newsList":[{"id":"2603216076","title":"Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2603216076","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603216076?lang=en_us&edition=fundamental","pubTime":"2026-01-15 09:25","pubTimestamp":1768440300,"startTime":"0","endTime":"0","summary":"Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation BTK protein degrader APG-3288 receives IND clearance f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/15/3219202/0/en/Ascentage-Pharma-Outlined-its-Global-Innovation-Strategy-During-Presentation-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","BK4581","LABU","XBI","LU2089284900.SGD","LU1074936037.SGD","LU1791710582.SGD","LU2271345857.HKD","LU1244550577.SGD","LU1244550494.USD","LU1732799900.SGD","LU2089283258.USD","LU1989772923.USD","LU1548497426.USD","LU2133065610.SGD","IE00BKVL7J92.USD","LU1732800096.USD","LU0158827948.USD","LU2347655156.SGD","LU1668664300.SGD","BK4137","LU1791710400.SGD","LU0267386448.USD","LU1363072403.SGD","BK4139","LU2111349929.HKD","LU0128526141.USD","HCSG","LU0795875169.SGD","LU1162221912.USD","IND","LU0158827781.USD","LU0106261372.USD","LU0006306889.USD","LU0882574139.USD","BK4588","BK4127","LU0795875086.SGD","LU2028103732.USD","BK4585","LU1720051108.HKD","LU0234570918.USD","AAPG","BK4534","LU0912757837.SGD","LU0314104364.USD","LU1989772840.SGD","LU0029874061.USD","XLV","LU0225283273.USD"],"gpt_icon":0},{"id":"2603598630","title":"Ascentage Pharma initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2603598630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603598630?lang=en_us&edition=fundamental","pubTime":"2026-01-14 04:20","pubTimestamp":1768335631,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $48 price target Published first on TheFly – the ultimate sour...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2601369153","title":"Piper Sandler Reaffirms Their Buy Rating on Ascentage Pharma Group International Unsponsored ADR (AAPG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369153?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:17","pubTimestamp":1767874648,"startTime":"0","endTime":"0","summary":"In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Ascentage Pharma Group International Unsponsored ADR, with a p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-ascentage-pharma-group-international-unsponsored-adr-aapg-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-ascentage-pharma-group-international-unsponsored-adr-aapg-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAPG"],"gpt_icon":0},{"id":"2601314871","title":"Ascentage Pharma Gets FDA's IND Clearance for APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601314871","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601314871?lang=en_us&edition=fundamental","pubTime":"2026-01-07 18:12","pubTimestamp":1767780754,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group (AAPG) said late Tuesday it has received an investigational new drug clearance from the US Food and Drug Administration for oncology drug candidate APG-3288.The company plans to advance the drug into a phase 1 trial in patients with relapsed/refractory B-cell malignancies.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1923622291.USD","AAPG","IND","APG","BK4129","LU2125909916.SGD","LU2125909759.SGD","BK4139"],"gpt_icon":0},{"id":"1146349455","title":"Hong Kong Stock Movement | ASCENTAGE-B (06855) Rises Nearly 4% as Novel BTK Degrader APG-3288's IND Application Receives US FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=1146349455","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146349455?lang=en_us&edition=fundamental","pubTime":"2026-01-07 11:10","pubTimestamp":1767755435,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) rose nearly 4%, and as of the time of writing, it was up 3.69% to HK$53.4, with a turnover of HK$61.6418 million.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909759.SGD","LU2125909916.SGD","AAPG","LU1923622291.USD","APG","BK4139","BK1161","06855","BK4129","BK1574"],"gpt_icon":0},{"id":"2601479768","title":"Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601479768","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601479768?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:00","pubTimestamp":1767747600,"startTime":"0","endTime":"0","summary":"Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has receivedinvestigational new drug (IND) clearancefrom the U.S. FDA, marking another major expansion to the comp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214213/0/en/Ascentage-Pharma-Announces-IND-Clearance-by-the-U-S-Food-and-Drug-Administration-for-BTK-Degrader-APG-3288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","PK","BCR","LU0289739343.SGD","LU2355687059.USD","BK4585","LU1923621640.USD","LU1712237335.SGD","LU2089279066.USD","LU0124676726.USD","LU1923622291.USD","LU2125909916.SGD","LU2229751404.USD","LU0472753341.HKD","LU2362540622.SGD","BK4139","IND","AAPG","LU0511384066.AUD","LU0689626769.HKD","LU0289961442.SGD","BK4129","LU2238339852.HKD","LU0057025933.USD","LU2211814178.USD","LU1939255532.USD","LU2362541513.USD","LU1585245621.USD","LU2125910336.SGD","LU1623119135.USD","BK4588","BK4181","LU2023250504.SGD","WM","LU1974910355.USD","LU1892829315.USD","BK4534","LU0069063385.USD","LU1989772840.SGD","LU2041044095.USD","BK4120","LU0347712357.USD","LU2125909759.SGD","LU2125910179.SGD","LU2413666699.HKD","LU1917777945.USD","LU2308191902.HKD","APG","LU1430594728.SGD","LU2240825500.USD"],"gpt_icon":0},{"id":"1168013082","title":"ASCENTAGE PHARMA GROUP-B (06855): David Sidransky to be Appointed as Lead Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1168013082","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168013082?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:50","pubTimestamp":1767106220,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA GROUP-B (06855) announced that Dr. Debra Yu will be appointed as an additional member of the Board Nomination Committee, effective December 26, 2025. Dr. David Sidransky will be...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1161","06855","BK1574","AAPG"],"gpt_icon":0},{"id":"1177837504","title":"CICC Maintains \"Outperform\" Rating on ASCENTAGE-B (06855) as POLARIS-1 Gains Approval in US and EU","url":"https://stock-news.laohu8.com/highlight/detail?id=1177837504","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177837504?lang=en_us&edition=fundamental","pubTime":"2025-12-17 11:57","pubTimestamp":1765943833,"startTime":"0","endTime":"0","summary":"CICC has reiterated its \"Outperform\" rating on ASCENTAGE-B (06855) with a target price of HK$89, citing positive progress in the company's R&D pipeline. The global Phase III study (POLARIS-1) for...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","AAPG","06855","BK1574","BK4139"],"gpt_icon":0},{"id":"2590677273","title":"ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590677273","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590677273?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapyMolecular responses continue to deepen with extended treatment duration, reaching 60% m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202020/0/en/ASH-2025-Updated-Data-for-Ascentage-Pharma-s-Olverembatinib-in-Second-Line-CML-CP-Showing-Encouraging-Potential-for-Early-Line-Treatment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4016","BK4109","BK4588","CP","BK4585","LU2463526074.USD","BK4139","LU1261432733.SGD","ASH","AAPG"],"gpt_icon":0},{"id":"2590367742","title":"ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367742","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590367742?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectivelyHigh-risk IKZF1plus patient","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202021/0/en/ASH-2025-Ascentage-Pharma-Presents-First-Dataset-from-Phase-III-POLARIS-1-Study-of-Olverembatinib-in-Newly-Diagnosed-Ph-ALL-Shows-a-Best-MRD-Negativity-CR-Rate-Exceeding-60.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALL","EMA","LU1699723380.USD","ASH","BK4139","BK4161","LU0985320562.USD","BK4109","LU2355687059.USD","BK4107","AAPG","III","BK4533","LU2463526074.USD","BK4081","BK4134","BK4588","CR","LU1571399168.USD","BK4585"],"gpt_icon":0},{"id":"2590367726","title":"ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367726","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590367726?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effect","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202022/0/en/ASH-2025-Ascentage-Pharma-Presents-Four-Year-Follow-Up-Data-from-Registrational-Phase-II-Study-of-Olverembatinib-Reaffirming-Differentiated-Long-Term-Efficacy-and-Safety-in-TKI-Res.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CHR","BK4016","LU2463526074.USD","BK4588","BK4109","CP","ASH","BK4585","BK4077","AAPG","LU1261432733.SGD"],"gpt_icon":0},{"id":"2589807890","title":"ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances","url":"https://stock-news.laohu8.com/highlight/detail?id=2589807890","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589807890?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:10","pubTimestamp":1765156200,"startTime":"0","endTime":"0","summary":"Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly diag","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201167/0/en/ASH-2025-Ascentage-Pharma-Presents-Encouraging-Data-from-Phase-Ib-II-Study-of-Bcl-2-Inhibitor-Lisaftoclax-in-Venetoclax-Exposed-Patients-with-Myeloid-Malignances.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097","ASH","BK4225","AAPG","BK4109","ORR","LU2463526074.USD","BK4203","HR","BK4139"],"gpt_icon":0},{"id":"2589066826","title":"Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589066826","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589066826?lang=en_us&edition=fundamental","pubTime":"2025-12-06 23:15","pubTimestamp":1765034100,"startTime":"0","endTime":"0","summary":"Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201070/0/en/Ascentage-Pharma-Presents-Pivotal-China-Registrational-Study-Data-for-Lisaftoclax-in-Oral-Report-at-2025-American-Society-of-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","ASH","ORR","BK4203","HR","BK4097","AAPG","BK4139","AFG","BK4225","BK4109","TLS","LU2463526074.USD","BK4107"],"gpt_icon":0},{"id":"1170778758","title":"HK Stock Movement | ASCENTAGE-B (06855) Rises Over 6% as POLARIS-1 Study for Olverembatinib (Nerlynx®) Gains FDA and EMA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1170778758","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170778758?lang=en_us&edition=fundamental","pubTime":"2025-12-05 09:38","pubTimestamp":1764898699,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) surged more than 6%, reaching HK$64.2 by the time of writing, with a trading volume of HK$19.93 million. The uptick follows the company's announcement on December 5 that its...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1574","AAPG","EMA","BK1161","BK4081","06855"],"gpt_icon":0},{"id":"1151522256","title":"ASCENTAGE PHARMA-B (06855) Receives FDA and EMA Approval for Global Phase III Trial of Olverembatinib (Nerlynx®) in First-Line Treatment of Ph+ ALL","url":"https://stock-news.laohu8.com/highlight/detail?id=1151522256","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151522256?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:08","pubTimestamp":1764893308,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA-B (06855) announced that its self-developed Class 1 innovative drug, olverembatinib (brand name: Nerlynx®), has received approval from the U.S. Food and Drug Administration (FDA) and...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","BK1574","LU1571399168.USD","06855","BK4139","ALL","AAPG","EMA","LU2355687059.USD","BK1161","BK4081","BK4107","BK4533","BK4585","BK4588","III","LU1699723380.USD","BK4134"],"gpt_icon":0},{"id":"2589550638","title":"Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2589550638","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589550638?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:00","pubTimestamp":1764892800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Dec.  04, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International(NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200415/0/en/Ascentage-Pharma-Announces-Global-Registrational-Phase-III-Study-of-Olverembatinib-in-First-Line-Treatment-of-Ph-ALL-Cleared-by-US-FDA-and-EMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0792757196.USD","BK4161","LU1929549753.HKD","LU0985320562.USD","EMA","LU1674673428.USD","ALL","IE00BFXG1179.USD","BK4017","BK4134","LU1599440770.SGD","LU1221951046.USD","BK4139","CDE","LU0868494708.USD","LU1894683348.USD","LU1066051225.USD","CR","BK4020","LU2286300806.USD","ASH","LU1571399168.USD","LU2237443382.USD","LU1880398471.USD","OS","LU1778281490.HKD","CSCO","III","BK4525","IE00BZ1G4Q59.USD","LU0868494617.USD","IE00BVYPNW00.USD","BK4581","LU1221951129.SGD","LU1244550221.USD","SG9999015986.USD","LU0348723411.USD","IE00B3PB1722.GBP","IE00BDGV0183.EUR","LU1244550577.SGD","IE00BFMHRM44.USD","LU0234570918.USD","LU2506952097.USD","BK4585","LU0234572021.USD","AAPG","BK4560","LU0203347892.USD","BK4579"],"gpt_icon":0},{"id":"2588720594","title":"Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720594","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720594?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594000,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Dec.  01, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196956/0/en/Ascentage-Pharma-to-Host-Webcast-Highlighting-Key-Data-from-ASH-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","BK4109","BK4139","LU2463526074.USD","AAPG","BK4181","BK4588","BK4585","HST","BK4218"],"gpt_icon":0},{"id":"1195526525","title":"ASCENTAGE PHARMA GROUP-B (06855) Grants 1.3045 Million Restricted Share Units and 736,600 Share Options","url":"https://stock-news.laohu8.com/highlight/detail?id=1195526525","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195526525?lang=en_us&edition=fundamental","pubTime":"2025-11-27 21:24","pubTimestamp":1764249856,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA GROUP-B (06855) announced that, as of the date of this announcement, it has granted 1.3045 million restricted share units under the 2022 Restricted Share Unit Plan to 146 selected...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK4139","BK1161","06855","BK1574"],"gpt_icon":0},{"id":"1126789920","title":"Hong Kong Stock: ASCENTAGE-B Rises Over 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126789920","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126789920?lang=en_us&edition=fundamental","pubTime":"2025-11-26 11:21","pubTimestamp":1764127283,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855.HK) surged more than 3% in Hong Kong trading. At the time of writing, the stock was up 3.04% to HK$64.35, with a turnover of HK$46.05 million.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","AAPG","06855","BK4139","BK1574"],"gpt_icon":0},{"id":"1182587677","title":"HK Stock Movement | ASCENTAGE-B (06855) Rises Over 3% as Study Reveals Novel Mechanism of Olverembatinib's Anti-Tumor Effects via Lipid Metabolism Regulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1182587677","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182587677?lang=en_us&edition=fundamental","pubTime":"2025-11-26 11:00","pubTimestamp":1764126017,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) surged more than 3%, reaching HK$64.35 by the time of writing, with a trading volume of HK$46.05 million. The company announced on November 25 that research findings from the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4139","AAPG","BK1574","06855"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentage.com","stockEarnings":[{"period":"1week","weight":-0.0601},{"period":"1month","weight":-0.0512},{"period":"3month","weight":-0.2367},{"period":"6month","weight":-0.3303},{"period":"1year","weight":0.5681},{"period":"ytd","weight":0.0309}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"ASCENTAGE PHARMA GROUP","nameEN":"ASCENTAGE PHARMA GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ASCENTAGE PHARMA GROUP(AAPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ASCENTAGE PHARMA GROUP(AAPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ASCENTAGE PHARMA GROUP,AAPG,ASCENTAGE PHARMA GROUP股票,ASCENTAGE PHARMA GROUP股票老虎,ASCENTAGE PHARMA GROUP股票老虎国际,ASCENTAGE PHARMA GROUP行情,ASCENTAGE PHARMA GROUP股票行情,ASCENTAGE PHARMA GROUP股价,ASCENTAGE PHARMA GROUP股市,ASCENTAGE PHARMA GROUP股票价格,ASCENTAGE PHARMA GROUP股票交易,ASCENTAGE PHARMA GROUP股票购买,ASCENTAGE PHARMA GROUP股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ASCENTAGE PHARMA GROUP(AAPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ASCENTAGE PHARMA GROUP(AAPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction